<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="367855">
  <stage>Registered</stage>
  <submitdate>12/02/2015</submitdate>
  <approvaldate>12/03/2015</approvaldate>
  <actrnumber>ACTRN12615000229572</actrnumber>
  <trial_identification>
    <studytitle>The effects of nasal decongestion on obstructive sleep apnoea severity in people with tetraplegia</studytitle>
    <scientifictitle>A proof-of-concept study of the effect of nasal phenyepherine versus placebo on the apnoea hypopnoea index in participants with tetraplegia and sleep apnoea</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Obstructive sleep apnoea</healthcondition>
    <healthcondition>Tetraplegia</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Sleep apnoea</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Single dose only of 0.5ml of 0.5% nasal phenyepherine spray delivered immediately prior to sleep. 
Intervention order will be randomised and there will be a one-week washout period between treatments. 
</interventions>
    <comparator>Single dose only of 0.5ml of normal saline nasal spray delivered immediately prior to sleep. 
</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The difference between the two treatment arms in the apnoea hypopnoea index (events per hour) obtained during the first 50% of the study nights. </outcome>
      <timepoint>The first 50% of the total sleep time on each of the two sleep studies</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The difference between the two treatment arms in the total apnoea hypopnoea index (events per hour) obtained during the study nights. 

</outcome>
      <timepoint>The total sleep time on each of the two sleep studies

</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Difference in nasal resistance as assessed using nasal rhinometry

</outcome>
      <timepoint>Immediately before and after instillation of either treatment A or B at the beginning of each study night.

</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Difference in subjective rating of nasal congestion (Modified Borg Congestion scale &amp; Nasal Congestion Questionnaire)
</outcome>
      <timepoint>Immediately before and after instillation of either treatment A or B at the beginning of each study night (Modified Borg Congestion scale) and in the evening before each of the sleep studies (Nasal Congestion Questionnaire).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Difference in the route of breathing (proportion of the respiratory events that are identified as being through the nasal versus oral route as assessed using nasal pressure and thermistor)
</outcome>
      <timepoint>The total sleep time on each of the two sleep studies

</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Difference in sleep quality as defined by the Arousal Index per hour of sleep in the first 50% of the study nights.
</outcome>
      <timepoint>The first 50% of the total sleep time on each of the two sleep studies</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The difference between the two treatment arms in the 4% desaturation rate as assessed using pulse oximetry (events per hour) obtained during the entire study nights. </outcome>
      <timepoint>The total sleep time on each of the two sleep studies</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Tetraplegia
obstructive sleep apnoea as defined as having an apnoea hypopnoea index of greater than 10 events per hour

</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Neurologic condition other than tetraplegia
Uncontrolled hypertension
Significant head injury
Ongoing hypercapnic ventilatory failure 
Allergy to phenylephrine or lignocaine 
Inability to provide informed consent
Fixed nasal obstruction (i.e. nasal fracture or deviated septum)
Use of other medication that could influence nasal patency
Use of bronchodilators or corticosteroid inhalers
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sequential enrollment of eligible participants identified from clinical unit records. 
Central, independent online treatment allocation</concealment>
    <sequence>Randomized order drug administration. Sequence generated on randomization.com</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>23/03/2015</anticipatedstartdate>
    <actualstartdate>6/02/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>15</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Austin Health</primarysponsorname>
    <primarysponsoraddress>155 Studley Rd. Heidelberg 3084 Vic</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council</fundingname>
      <fundingaddress>GPO Box 1421
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Charities/Societies/Foundations</sponsortype>
      <sponsorname>Institute for Breathing and Sleep </sponsorname>
      <sponsoraddress>Bowen Centre. Austin Health, 155 Studley Rd. Heidelberg 3084 Vic</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study will trial a common nasal decongestant to determine its effect on OSA severity in people with tetraplegia. </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>South Eastern Sydney Local Health District HREC</ethicname>
      <ethicaddress>Room G71 East Wing
Edmund Blacket Building
Prince of Wales Hospital
RANDWICK NSW 2031
</ethicaddress>
      <ethicapprovaldate>24/06/2014</ethicapprovaldate>
      <hrec>141032 (HREC/14|POWH/Ã­33)</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>David Berlowitz</name>
      <address>Institute for Breathing and Sleep
Bowen Centre
155 Studley Rd
Austin Health
Heidelberg 3084 Vic</address>
      <phone>+61394963877</phone>
      <fax />
      <email>david.berlowitz@austin.org.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>David Berlowitz</name>
      <address>Institute for Breathing and Sleep
Bowen Centre
155 Studley Rd
Austin Health
Heidelberg 3084 Vic</address>
      <phone>+61394963877</phone>
      <fax />
      <email>david.berlowitz@austin.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>David Berlowitz</name>
      <address>Institute for Breathing and Sleep
Bowen Centre
155 Studley Rd
Austin Health
Heidelberg 3084 Vic</address>
      <phone>+61394963877</phone>
      <fax />
      <email>david.berlowitz@austin.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>